Kotaro Suzuki1, Tomoaki Terakawa2, Naoe Jimbo3, Rena Inaba3, Yuzo Nakano1, Masato Fujisawa1. 1. Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. 2. Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan daatera0804@yahoo.co.jp. 3. Division of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract
BACKGROUND/AIM: The development of treatment-related neuroendocrine prostate cancer (t-NEPC) is an increasing clinical concern. The objectives were to clarify the clinical features of t-NEPC. PATIENTS AND METHODS: A total of 9 patients with histologically confirmed t-NEPC were reviewed. RESULTS: Of these 9 patients, 2 patients were diagnosed with t-NEPC by a histological examination without elevation in blood tumor marker levels. Immunohistochemistry revealed an acquired Rb loss in 5 patients. All patients were treated with platinum-based chemotherapy as first-line treatment and 6 patients received concurrent radiation therapy (RT). The median cancer-specific survival was 14.4 months, and 7 patients achieved an objective response. Patients with tumor-infiltrating CD8+ lymphocyte (CD8+-TILs) showed better response than those without CD8+-TILs. CONCLUSION: We described the clinical features of histologically confirmed t-NEPC. In addition to the importance of biopsy, we showed that platinum-based chemotherapy plus RT had a favorable cytoreductive effect. Further clinical recognition and studies are needed. Copyright
BACKGROUND/AIM: The development of treatment-related neuroendocrine prostate cancer (t-NEPC) is an increasing clinical concern. The objectives were to clarify the clinical features of t-NEPC. PATIENTS AND METHODS: A total of 9 patients with histologically confirmed t-NEPC were reviewed. RESULTS: Of these 9 patients, 2 patients were diagnosed with t-NEPC by a histological examination without elevation in blood tumor marker levels. Immunohistochemistry revealed an acquired Rb loss in 5 patients. All patients were treated with platinum-based chemotherapy as first-line treatment and 6 patients received concurrent radiation therapy (RT). The median cancer-specific survival was 14.4 months, and 7 patients achieved an objective response. Patients with tumor-infiltrating CD8+ lymphocyte (CD8+-TILs) showed better response than those without CD8+-TILs. CONCLUSION: We described the clinical features of histologically confirmed t-NEPC. In addition to the importance of biopsy, we showed that platinum-based chemotherapy plus RT had a favorable cytoreductive effect. Further clinical recognition and studies are needed. Copyright
Authors: Mark P Labrecque; Joshi J Alumkal; Ilsa M Coleman; Peter S Nelson; Colm Morrissey Journal: Endocr Relat Cancer Date: 2021-07-15 Impact factor: 5.900
Authors: Jennifer Moritz; Thomas Bauernhofer; Sebastian Mannweiler; Tanja Langsenlehner; Karl Pummer; Nadia Dandachi; Martin Pichler Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155